Peptide exosite inhibitors of factor VIIa as anticoagulants

被引:0
|
作者
Mark S. Dennis
Charles Eigenbrot
Nicholas J. Skelton
Mark H. Ultsch
Lydia Santell
Mary A. Dwyer
Mark P. O'Connell
Robert A. Lazarus
机构
[1] Genentech Inc.,Department of Protein Engineering
[2] University of Chicago,Department of Biochemistry and Molecular Biology
来源
Nature | 2000年 / 404卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Potent anticoagulants have been derived by targeting the tissue factor–factor VIIa complex with naive peptide libraries displayed on M13 phage. The peptides specifically block the activation of factor X with a median inhibitory concentration of 1 nM and selectively inhibit tissue-factor-dependent clotting. The peptides do not bind to the active site of factor VIIa; rather, they work by binding to an exosite on the factor VIIa protease domain, and non-competitively inhibit activation of factor X and amidolytic activity. One such peptide (E-76) has a well defined structure in solution determined by NMR spectroscopy that is similar to the X-ray crystal structure when complexed with factor VIIa. These structural and functional studies indicate an allosteric ‘switch’ mechanism of inhibition involving an activation loop of factor VIIa and represent a new framework for developing inhibitors of serine proteases.
引用
收藏
页码:465 / 470
页数:5
相关论文
共 50 条
  • [41] The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
    Meeks, Shannon L.
    Leissinger, Cindy A.
    HAEMOPHILIA, 2019, 25 (06) : 911 - 918
  • [42] Novel 5-azaindole factor VIIa inhibitors
    Riggs, JR
    Hu, HY
    Kolesnikov, A
    Leahy, EM
    Wesson, KE
    Shrader, WD
    Vijaykumar, D
    Wahl, TA
    Tong, ZW
    Sprengeler, PA
    Green, MJ
    Yu, C
    Katz, BA
    Sanford, E
    Nguyen, M
    Cabuslay, R
    Young, WB
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (12) : 3197 - 3200
  • [43] Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors
    Zbinden, KG
    Obst-Sander, U
    Hilpert, K
    Kühne, H
    Banner, DW
    Böhm, HJ
    Stahl, M
    Ackermann, J
    Alig, L
    Weber, L
    Wessel, HP
    Riederer, MA
    Tschopp, TB
    Lavé, T
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (23) : 5344 - 5352
  • [44] Recombinant Factor VIIa to Manage Major Bleeding from Newer Parenteral Anticoagulants
    Vavra, Kellie A.
    Lutz, Mark F.
    Smythe, Maureen A.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (04) : 718 - 726
  • [45] Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors
    Zbinden, KG
    Banner, DW
    Ackermann, J
    D'Arcy, A
    Kirchhofer, D
    Ji, YH
    Tschopp, TB
    Wallbaum, S
    Weber, L
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (03) : 817 - 822
  • [46] Factor XI inhibitors: a new class of anticoagulants
    Connors, Jean M.
    BLOOD ADVANCES, 2025, 9 (01) : 192 - 192
  • [47] Effect of a carboxy-terminal peptide on factor VIIA activity
    Monroe, D. M.
    Binder, L.
    Hoffman, M.
    Hart, G.
    Hoffman, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 706 - 706
  • [48] Bifunctional peptide boronate inhibitors of thrombin: Crystallographic analysis of inhibition enhanced by linkage to an exosite 1 binding peptide
    Skordalakes, E
    Elgendy, S
    Goodwin, CA
    Green, D
    Scully, MF
    Kakkar, VV
    Freyssinet, JM
    Dodson, G
    Deadman, JJ
    BIOCHEMISTRY, 1998, 37 (41) : 14420 - 14427
  • [49] Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency
    Scharrer, I
    HAEMOPHILIA, 1999, 5 (04) : 253 - 259
  • [50] Solid-phase synthesis of naphthylamidines as factor VIIa/tissue factor inhibitors
    Buckman, BO
    Chou, YL
    McCarrick, M
    Liang, A
    Lentz, D
    Mohan, R
    Morrissey, MM
    Shaw, KJ
    Trinh, L
    Light, DR
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (09) : 2249 - 2252